Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
21 03 2019
Historique:
received: 28 08 2018
accepted: 21 02 2019
entrez: 24 3 2019
pubmed: 25 3 2019
medline: 10 5 2020
Statut: epublish

Résumé

Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and controls will aid in understanding AD development in DS. We explored group differences in plasma concentrations of amyloid-β peptides and tau (as their accumulation is a characteristic feature of AD) and cytokines (as the inflammatory response has been implicated in AD development, and immune dysfunction is common in DS). We used ultrasensitive assays to compare plasma concentrations of the amyloid-β peptides Aβ Aβ Concentrations of Aβ

Sections du résumé

BACKGROUND
Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and controls will aid in understanding AD development in DS. We explored group differences in plasma concentrations of amyloid-β peptides and tau (as their accumulation is a characteristic feature of AD) and cytokines (as the inflammatory response has been implicated in AD development, and immune dysfunction is common in DS).
METHODS
We used ultrasensitive assays to compare plasma concentrations of the amyloid-β peptides Aβ
RESULTS
CONCLUSIONS
Concentrations of Aβ

Identifiants

pubmed: 30902060
doi: 10.1186/s13195-019-0477-0
pii: 10.1186/s13195-019-0477-0
pmc: PMC6429702
doi:

Substances chimiques

Amyloid beta-Peptides 0
Apolipoproteins E 0
Biomarkers 0
Cytokines 0
MAPT protein, human 0
tau Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26

Subventions

Organisme : Medical Research Council
ID : MR/K01417X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S011277/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L501542/1
Pays : United Kingdom
Organisme : Parkinson's UK
ID : G-0907
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026004/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R024901/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701075
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901254
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098330/Z/12/Z
Pays : United Kingdom

Investigateurs

Andre Strydom (A)
Elizabeth Fisher (E)
Dean Nizetic (D)
John Hardy (J)
Victor Tybulewicz (V)
Annette Karmiloff-Smith (A)
Tamara Al-Janabi (T)
David Zhang (D)

Références

Nat Genet. 2013 Dec;45(12):1452-8
pubmed: 24162737
Histopathology. 1988 Aug;13(2):125-37
pubmed: 2971602
Alzheimers Dement. 2017 May;13(5):541-549
pubmed: 27755974
Int J Immunogenet. 2010 Aug;37(4):233-7
pubmed: 20477881
Neurology. 2010 Nov 2;75(18):1639-44
pubmed: 21041786
Oncotarget. 2017 Sep 19;8(48):84489-84496
pubmed: 29137441
J Neurol Sci. 2007 Mar 15;254(1-2):22-7
pubmed: 17275850
Neurosci Lett. 1998 Jan 23;241(1):13-6
pubmed: 9502204
JAMA Neurol. 2019 Feb 1;76(2):152-160
pubmed: 30452522
Nat Rev Neurosci. 2015 Sep;16(9):564-74
pubmed: 26243569
Neurosci Lett. 2017 Jan 1;636:254-257
pubmed: 27851899
Ann Neurol. 1999 Apr;45(4):537-41
pubmed: 10211483
Ann Neurol. 1998 Mar;43(3):380-3
pubmed: 9506555
Neurosci Lett. 2009 Feb 20;451(2):162-4
pubmed: 19111900
J Alzheimers Dis. 2011;23(3):399-409
pubmed: 21116050
Neurol Ther. 2017 Jul;6(Suppl 1):15-24
pubmed: 28733960
Arch Neurol. 2007 Jul;64(7):1007-13
pubmed: 17620492
Nat Genet. 2011 May;43(5):429-35
pubmed: 21460840
Nat Genet. 2009 Oct;41(10):1088-93
pubmed: 19734902
Neurosci Lett. 2009 Jul 17;458(2):60-4
pubmed: 19442877
Neurobiol Aging. 2012 Sep;33(9):1988-94
pubmed: 21958962
J Neuroinflammation. 2013 Jul 16;10:84
pubmed: 23866266
J Pediatr (Rio J). 2017 Jan - Feb;93(1):100-104
pubmed: 27770619
PLoS One. 2017 Nov 30;12(11):e0188802
pubmed: 29190730
Wellcome Open Res. 2016 Nov 15;1:11
pubmed: 28018980
Lancet Neurol. 2018 Oct;17(10):860-869
pubmed: 30172624
Biol Psychiatry. 2010 Nov 15;68(10):930-41
pubmed: 20692646
PLoS One. 2010 Nov 15;5(11):e13950
pubmed: 21085570
Neurobiol Aging. 2004 Aug;25(7):833-41
pubmed: 15212837
F1000Res. 2016 May 12;5:
pubmed: 27239286
Ann Neurol. 1997 Feb;41(2):271-3
pubmed: 9029078
Front Aging Neurosci. 2018 Dec 11;10:409
pubmed: 30618716
Free Radic Biol Med. 2018 Jan;114:3-9
pubmed: 28870521
Sci Rep. 2016 May 31;6:26801
pubmed: 27241045
Alzheimer Dis Assoc Disord. 2010 Jan-Mar;24(1):96-100
pubmed: 19571731
Alzheimers Dement (Amst). 2017 Sep 12;8:179-187
pubmed: 28948206
Neurodegener Dis. 2017;17(4-5):227-234
pubmed: 28719891
Alzheimers Dement. 2016 Nov;12(11):1132-1148
pubmed: 27452424
Eur Cytokine Netw. 2012 Jun;23(2):64-7
pubmed: 22728286
Neurology. 2015 Aug 18;85(7):626-33
pubmed: 26180139
Neuro Endocrinol Lett. 2006 Dec;27(6):773-8
pubmed: 17187019
Neuron. 1991 Apr;6(4):487-98
pubmed: 1673054
Clin Exp Immunol. 2009 May;156(2):189-93
pubmed: 19250275
Front Behav Neurosci. 2015 Sep 14;9:239
pubmed: 26441570
J Intellect Disabil Res. 2014 Jan;58(1):61-70
pubmed: 23902161
J Alzheimers Dis. 2017;56(2):459-470
pubmed: 27983553
Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):315-8
pubmed: 19571732
PLoS One. 2014 Jun 05;9(6):e97709
pubmed: 24901945
Ann Neurol. 2016 Jan;79(1):110-9
pubmed: 26505746
J Intellect Disabil Res. 2007 Jun;51(Pt. 6):463-77
pubmed: 17493029
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Neurosci Lett. 2003 May 22;342(3):155-8
pubmed: 12757888
Arch Dis Child. 2004 Nov;89(11):1014-7
pubmed: 15499053
Acta Neuropathol. 2018 Oct;136(4):569-587
pubmed: 29770843
Int J Geriatr Psychiatry. 2010 Feb;25(2):202-7
pubmed: 19513990
Brain. 2018 Aug 1;141(8):2457-2474
pubmed: 29945247
Alzheimers Res Ther. 2018 Apr 10;10(1):39
pubmed: 29631614
J Alzheimers Dis. 2018;61(2):717-728
pubmed: 29226868
Nature. 2018 Feb 8;554(7691):249-254
pubmed: 29420472
Neurology. 2009 Sep 15;73(11):847-53
pubmed: 19752451
Front Aging Neurosci. 2017 Jan 17;8:316
pubmed: 28144219
J Alzheimers Dis. 2015;43(3):871-91
pubmed: 25125467
Am J Med Genet. 2000 Nov 27;95(3):224-8
pubmed: 11102927
Neurology. 2009 Sep 8;73(10):768-74
pubmed: 19738171
J Alzheimers Dis. 2012;31(2):277-83
pubmed: 22561328
Eur J Hum Genet. 2013 Sep;21(9):1016-9
pubmed: 23321618
J Neuroendocrinol. 2011 May;23(5):450-5
pubmed: 21362068
Trends Pharmacol Sci. 1991 Oct;12(10):383-8
pubmed: 1763432
Arch Neurol. 2004 May;61(5):668-72
pubmed: 15148142
Biomark Med. 2018 Jul;12(7):799-812
pubmed: 29902934
Sci Rep. 2017 Jan 10;7:40263
pubmed: 28071698
JAMA Neurol. 2017 May 1;74(5):557-566
pubmed: 28346578
Alzheimers Dement. 2017 Aug;13(8):841-849
pubmed: 28734653
J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):788-9
pubmed: 12754353
Alzheimers Dement. 2019 Feb;15(2):245-257
pubmed: 30503169
Neurosci Lett. 2001 Apr 6;301(3):199-203
pubmed: 11257432

Auteurs

Carla M Startin (CM)

Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK. carla.startin.09@ucl.ac.uk.
Division of Psychiatry, University College London, London, UK. carla.startin.09@ucl.ac.uk.
The LonDownS Consortium (London Down Syndrome Consortium), London, UK. carla.startin.09@ucl.ac.uk.

Nicholas J Ashton (NJ)

Maurice Wohl Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
NIHR Biomedical Research Centre for Mental Health, Biomedical Research Unit for Dementia at South London, and Maudsley NHS Foundation, London, UK.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Wallenberg Centre for Molecular & Translational Medicine, University of Gothenburg, Gothenburg, Sweden.

Sarah Hamburg (S)

Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK.
Division of Psychiatry, University College London, London, UK.
The LonDownS Consortium (London Down Syndrome Consortium), London, UK.

Rosalyn Hithersay (R)

Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK.
Division of Psychiatry, University College London, London, UK.
The LonDownS Consortium (London Down Syndrome Consortium), London, UK.

Frances K Wiseman (FK)

The LonDownS Consortium (London Down Syndrome Consortium), London, UK.
Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.

Kin Y Mok (KY)

The LonDownS Consortium (London Down Syndrome Consortium), London, UK.
Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Division of Life Science, Hong Kong University of Science and Technology, Hong Kong, SAR, People's Republic of China.

John Hardy (J)

The LonDownS Consortium (London Down Syndrome Consortium), London, UK.
Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Reta Lila Weston Institute, Institute of Neurology, University College London, London, UK.

Alberto Lleó (A)

Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Simon Lovestone (S)

Department of Psychiatry, University of Oxford, Oxford, UK.

Lucilla Parnetti (L)

Centre for Memory Disturbances, Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
UK Dementia Research Institute at UCL, London, UK.

Abdul Hye (A)

Maurice Wohl Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
NIHR Biomedical Research Centre for Mental Health, Biomedical Research Unit for Dementia at South London, and Maudsley NHS Foundation, London, UK.

André Strydom (A)

Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK.
Division of Psychiatry, University College London, London, UK.
The LonDownS Consortium (London Down Syndrome Consortium), London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH